Details of the Drug Reposition

General Information of This Drug (ID: DMU6NBO)

• Drug Name: APX3330 (DMU6NBO)
• Synonyms: E3330; 136164-66-4; E-3330; E 3330; CHEMBL578390; UNII-11267UI968; 11267UI968; (2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylidene]undecanoic acid; (E)-2-((4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylene)undecanoic acid; (2E)-3-(5-(2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl))-2-nonyl-2-propenoic acid; SCHEMBL3758716; SCHEMBL3758719; HMS3886N15; APX 3330; EX-A2212; BDBM50303955; s7445; ZINC14252145; CCG-268389; HY-19357; B5875; CS-0015424; E3330, >=98% (HPLC); A14440; (E)-3-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dienyl)-2-nonylpropenoic acid; (E)-3-(5,6-Dimethoxy-3-methyl-14-dioxocyclohexa-25-dienyl)-2-nonylpropenoic Acid; Undecanoic acid, 2-((4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methylene)-, (E)-
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Diabetic retinopathy	DISHGUJM	9B71.0	Phase 2	[1]

1 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Solid tumour/cancer	DISZR48F	2A00-2F9Z	Phase 1	[2]

References

• [1] ClinicalTrials.gov (NCT04692688) Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy (ZETA-1). U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT03375086) A Study of APX3330 in Patients With Advanced Solid Tumors (APX3330). U.S. National Institutes of Health.